title: Phase II study on DuP 937 (Teloxantrone) in colorectal carcinoma. A Canadian National Cancer Institute Clinical Trial Group study.
authors.affiliation: Ottawa Regional Cancer Centre, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Maroun
authors.forename: J
authors.initials: J
authors.lastname: Skillings
authors.forename: R
authors.initials: R
authors.lastname: MacCormick
authors.forename: M
authors.initials: M
authors.lastname: Potvin
authors.forename: G
authors.initials: G
authors.lastname: Wielgosz
authors.forename: J R
authors.initials: JR
authors.lastname: Davidson
authors.forename: E
authors.initials: E
authors.lastname: Eisenhauer
mesh_terms: D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011720:Pyrazoles / Q000627:therapeutic use*
chemical_list: D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; C046658:teloxantrone